23:51 , Feb 15, 2019 |  BC Extra  |  Company News

Bayer claims full rights to Vitrakvi from Lilly’s Loxo

Eli Lilly and Co. (NYSE:LLY) gained two fewer assets from its acquisition of Loxo Oncology Inc. than planned, as Loxo partner Bayer AG (Xetra:BAYN) said Friday it will exercise a change-of-control option to acquire full...
19:48 , Feb 15, 2019 |  BC Week In Review  |  Company News

ZappRx, Teva partner to increase patient access to specialty respiratory drugs

The Teva Respiratory LLC unit of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to streamline prescription of Teva’s specialty respiratory medications. Financial terms were...
21:17 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and rat studies identified a benzimidazole-based PTGER4 antagonist that could help treat pain. High throughput screening of Bayer AG's compound library, in vitro enzymatic activity assays and optimization of hits yielded...
16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies identified an aryloxytetramethylcyclobutane-based degrader of androgen receptor that could help treat prostate cancer. Chemical synthesis and testing in three prostate cancer cells lines of analogs of a...
16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and cell culture studies suggest inhibiting MGMT or its downstream mediator USP17L2 alone or in combination with HDAC inhibitors could help treat ovarian cancer. In patients, high tumor expression of...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
18:58 , Feb 1, 2019 |  BioCentury  |  Finance

Discovering Dewpoint's protein organizers

An experienced team and a drug discovery platform targeting biomolecular condensates enabled Dewpoint Therapeutics to raise $60 million in a series A round led by founding investor Polaris Partners. Samsara BioCapital, 6 Dimensions Capital, EcoR1...
01:20 , Feb 1, 2019 |  BC Week In Review  |  Financial News

Dewpoint launches with $60M series A to target biomolecular condensates

Dewpoint Therapeutics (Cambridge, Mass.) launched Jan. 30 with a $60 million series A round to fund development of its therapies targeting biomolecular condensates. Condensates are cellular organelles that concentrate and organize proteins and nucleic acids,...
00:53 , Feb 1, 2019 |  BC Innovations  |  Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
14:01 , Jan 30, 2019 |  BC Extra  |  Financial News

Dewpoint launches with $60M series A to target biomolecular condensates

Dewpoint Therapeutics (Cambridge, Mass.) launched Wednesday with a $60 million series A round to fund development of its therapies targeting biomolecular condensates. Condensates are cellular organelles that concentrate and organize proteins and nucleic acids, which...